SIGA Technologies, Inc. (SIGA)
SIGA Technologies, Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in New York City, NY, US. The stock last traded at $2.85, down 0.87% on the session, giving a market capitalisation of $204.8M. On trailing twelve-month figures it carries a trailing P/E of -65.48, a net margin of -5.1%. Its beta of 0.89 implies it has historically moved less than the broad market.
SIGA Technologies, Inc. is a pharmaceutical company with commercialized products, specializing in the health security and infectious disease sectors across the United States. A core offering is TPOXX, an oral antiviral drug formulated to combat human smallpox, a condition caused by the variola virus. Furthermore, the company has forged a strategic collaboration with Cipla Therapeutics. This partnership aims to ensure ongoing innovation and accessibility of antibacterial treatments, particularly those designed to counter biothreats. Founded in 1995, SIGA Technologies' corporate headquarters are located in New York, New York.
SIGA Technologies, Inc. is most often compared with the following Healthcare names: